Innovative Medicines Canada, an association that represents drugmakers in Canada, has challenged the overhaul of Canada’s drug-pricing regime.
The US Court of Appeals for the Federal Circuit has ruled that claims in an Allergan patent detailing the results of a glaucoma treatment are material to its patentability, after an unsuccessful invalidation appeal brought by Sandoz.
The Delhi High Court has cleared the way for a generic version of Novartis’ small-cell lung cancer drug Ceritinib, after the Swiss pharmaceutical company’s patent was revoked.
The US Patent Trial and Appeal Board has instituted an inter partes review into a patent covering an opioid overdose treatment owned by Nalox-1 Pharmaceuticals.
A Takeda subsidiary cannot overturn a $155 million jury verdict that it infringed one of Bayer’s patents, a district court has ruled.
Gilead Sciences, the maker of HIV drug Truvada, has asked the US Patent and Trademark Office to review patents granted to the government covering preventative use of the drug.
Danish pharmaceutical company Novo Nordisk has sued Mylan in a US court over a proposed generic of diabetes drug Victoza (liraglutide).
Amneal and three other generic makers have agreed to pay $1.54 million to settle a class-action lawsuit, which alleged the companies engaged in an unlawful scheme to maintain their monopoly over an Alzheimer’s drug.
The US Court of Appeals for the Federal Circuit yesterday, August 15, blocked Actavis’s attempt to market a generic version of Nalpropion Pharmaceuticals’ weight-loss drug Contrave.
Sanofi secured a win at the US Court of Appeals for the Federal Circuit yesterday, August 14, after the appeals court concluded a lower court lacked authority to invalidate claims of a patent covering a prostate cancer drug.